ClinicalTrials.gg
Active, not recruitingNCT03876769CASSIOPEIAUpdated Aug 19, 2026

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

A Phase 2 interventional study of CTL019 in B-Cell Acute Lymphoblastic Leukemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 43 sites in 11 countries. Open to participants aged 1 Year to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Not applicable
Ages
1 Year to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Burkitt Lymphoma by Novartis — 2 open to participants now, 4 under way, 1 of them phase 3. Burkitt Lymphoma · Novartis.

Enrollment
2nd of 11
121 · median 60
Started
2019
with 2 others
Phase 2
7 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Burkitt Lymphoma by Novartis, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2019, is one of 7 in phase 2, and was the 7th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

2 of the 12 studies in Burkitt Lymphoma by Novartis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Burkitt Lymphoma by Novartis, or all of them as a file.
02

Study summary

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment \& follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Efficacy and safety will be assessed at study visits and as clinically indicated throughout the study. The study is expected to end in approximately 8 years after first patient first treatment (FPFT). A post-study long term follow-up safety will continue under a separate protocol per health authority guidelines.

03

Conditions studied

  • B-Cell Acute Lymphoblastic Leukemia

Keywords

  • CTL019
  • Kymriah
  • B-Cell Acute Lymphoblastic Leukemia
  • ALL
  • tisagenlecleucel
  • HR B-ALL EOC MRD
  • Minimal Residual Disease (MRD)
  • Positive at the End of Consolidation (EOC)
04

Who can participate

Ages eligible
1 Year to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CD19 expressing B-cell Acute Lymphoblastic Leukemia
  2. De novo NCI HR B-ALL who received treatment and are MRD ≥ 0.01% at EOC. EOC bone marrow MRD will be collected prior to screening and will be assessed by multi-parameter flow cytometry using central laboratory analysis.
  3. Age 1 to 25 years at the time of screening
  4. Lansky (age \< 16 years) or (age ≥ 16 years) performance status ≥ 60%
  5. Adequate organ function during the screening period:

    A. Renal function based on age/gender B. ≤ 5 times for age C. AST ≤ 5 times ULN for age D. Total \< 2 mg/dL (for Gilbert's Syndrome subjects total bilirubin \< 4 mg/dL)

    E. Adequate pulmonary function defined as:

    • no or mild dyspnea (≤ Grade 1)
    • oxygen saturation of > 90% on room air F. Adequate cardiac function defined as LVSF ≥ 28% confirmed by echocardiogram or ≥ 45% confirmed by echocardiogram or MUGA within 6 weeks of screening
  6. Prior induction and consolidation chemotherapy allowed: 1st line subjects: ≤ 3 blocks of standard chemotherapy for first-line B-ALL, defined as 4-drug induction, Berlin-Frankfurt-Münster (BFM) consolidation or Phase 1b, and interim maintenance with high-dose methotrexate.

Exclusion criteria

Exclusion Criteria:

  1. M3 marrow at the completion of induction therapy
  2. M2 or M3 marrow or persistent extramedullary disease at the completion of first-line consolidation therapy or evidence of disease progression in the peripheral blood or new extramedullary disease prior to enrollment. Patients with previous CNS disease are eligible if there is no active CNS involvement of leukemia at the time of screening.
  3. Philadelphia chromosome positive ALL
  4. Hypodiploid: less than 44 chromosomes and/or DNA index \< 0.81, or other clear evidence of a hypodiploid clone
  5. Prior tyrosine kinase inhibitor therapy
  6. Subjects with concomitant genetic syndromes associated with bone marrow failure states: such as subjects with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Subjects with Down syndrome will not be excluded.
  7. Subjects with Burkitt's lymphoma/leukemia (i.e. subjects with mature B-ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)
  8. Has had treatment with any prior anti-CD19 therapy 9. Treatment with any prior gene or engineered T cell therapy

Other protocol-defined inclusion/exclusion may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Single dose of CTL019

    Based on the subject's weight one of two possible dose ranges will be prepared for the subject: Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight OR Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells

    Biological: CTL019

Interventions

  • BiologicalTisagenlecleucelStudies of TisagenlecleucelTisagenlecleucel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Based on the subject's weight, one of two possible dose ranges will be prepared for the subject: Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight OR Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells

06

What researchers measure

Primary outcomes

  1. Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission

    DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause. Participants are not censored at the start of subsequent anticancer therapy or SCT while in remission.

    Time frame: 5 years after tisagenlecleucel infusion

  2. Overall Survival (OS) rate

    OS is defined as the time from date of first tisagenlecleucel infusion to the date of death due to any reason.

    Time frame: 4 years after tisagenlecleucel

Secondary outcomes

  1. Percentage of participants who are disease free without allogeneic stem cell transplant (SCT)

    Minimal Residual Disease (MRD) negative remission (complete remission (CR) or Complete remission with incomplete blood count recovery CRi)) at Month 12 without SCT after tisagenlecleucel infusion.

    Time frame: 12 months after last infusion

  2. DFS rate with censoring for new anticancer therapy, including SCT, while in remission

    Assessing the effect of tisagenlecleucel on DFS if new anticancer therapy is not available.

    Time frame: 5 years

  3. Percentage of participants achieving MRD negative CR or CRi at Month 3

    Assessing the percentage of participants who achieved MRD negative complete response (CR) or Complete remission with incomplete blood count recovery (CRi) status as determined by central laboratory using multi-parameter flow cytometry.

    Time frame: 3 months after the tisagenlecleucel infusion.

  4. Pediatric Quality of Life (PedsQL)

    Patient reported outcome to assess quality of life in patients aged 8 and above. The 23 items PedQL (Pediatrics Quality of Life Inventory) measure core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. Items measured include 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items). Each item is measured on a 5 point Likert scale with 0 indicating "never" and 4 indicating "almost always". The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 5=25, and 4=0. A higher score indicates better health-related quality of life (HRQoL).

    Time frame: 5 years

  5. European Quality of Life 5 dimensions (EQ-5D-3L & EQ-5D-Y))

    Patient reported outcome to assess health status in patients aged 8 and above. The EQ-5D (European Quality of Life -5 Dimensions) measures a wide range of health conditions and treatments; it is composed of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (EQ-visual analogue scale \[EQ-VAS\]) that records the patient's self-rated overall health state. Respondents rate each of these 5 dimensions from "no problem", "some problem," or "extreme problem". The EQ-VAS records the respondents' self-related health on a vertical, visual analogue scale. The range for EQ-VAS is from 0 (=the worst health you can imagine) to 100 (=the best health you can imagine).

    Time frame: 5 years

  6. Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Detection test

    Speed of performance (mean of the log10 transformed reaction times for correct responses)

    Time frame: 5 years

  7. Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Identification test

    This test measures the speed of performance (mean of the log10 transformed reaction times for correct responses)

    Time frame: 5 years

  8. Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Groton Maze Learning test

    This test looks at the total number of errors made in attempting to learn the hidden pathways during a single session.

    Time frame: 5 years

  9. Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: One Back test

    This test measures the accuracy of performance (arcsine transformation of the square root of the percentage of correct responses). The test also measures the speed of performance (mean of the log10 transformed reaction times for correct responses).

    Time frame: 5 years

  10. Impact of tisagenlecleucel on cognitive functioning usingComputerized neurocognitive assessment: One card learning test

    This test measures the accuracy of performance (arcsine transformation of the square root of the proportion of correct responses).

    Time frame: 5 years

  11. Percentage of participants with pre-existing antibodies

    Prevalence of immunogenicity

    Time frame: 8 years

  12. Percentage of participants with anti-m CAR19 antibodies post infusion with tisagenlecleucel and % of patients without measureable anti-mCAR19 antibodies

    Incidence of immunogenicity

    Time frame: 8 years

  13. Percentage of patients that have measureable anti-mCAR19 antibodies above patient specific cut-point (reported as a %) pre and post tisagenlecleucel infusion categorized by Day 28 response

    Impact of immunogenicity on clinical response

    Time frame: 8 years

  14. tisagenlecleucel transgene concentration

    Transgene concentration as detected by qPCR in target tissue

    Time frame: 8 years

  15. Expression of tisagenlecleucel

    Summary of tisagenlecleucel CAR-positive viable T cells measured by flow cytometry in target tissue

    Time frame: 8 years

  16. Persistence of CAR (reported as copies/ug) categorized by the time to B-cell recovery (recovery < 3 months, >3 months to < 6months, > 6 months)

    Relationship between B-cell recovery and transgene levels

    Time frame: 8 years

  17. Cmax; cellular kinetic parameter of tisagenlecleucel

    Cmax is the maximum (peak) observed peripheral blood or other body fluid drug concentration after single dose administration.

    Time frame: 8 years

  18. Tmax; cellular kinetic parameter of tisagenlecleucel

    Tmax is the time to maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days)

    Time frame: 8 years

  19. AUC0-29d and 84d; cellular kinetic parameter of tisagenlecleucel

    The AUC from time zero to day 29 and 84 or other disease assessment days, in peripheral blood (% or copies/μg x days )

    Time frame: 8 years

  20. AUC0-Tmax; cellular kinetic parameter of tisagenlecleucel

    The AUC from time zero to Tmax in peripheral blood (% or copies/μg x days)

    Time frame: 8 years

  21. T1/2; cellular kinetic parameter of tisagenlecleucel

    The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood

    Time frame: 8 years

  22. Clast; cellular kinetic parameter of tisagenlecleucel

    The last observed quantifiable concentration in peripheral blood (% or copies/μg)

    Time frame: 8 years

  23. Tlast; cellular kinetic parameter of tisagenlecleucel

    The time of last observed quantifiable concentration in peripheral blood (days)

    Time frame: 8 years

  24. Impact of tisagenlecleucel dose on day 29 response

    Clinical response summarized by quartile of administered doses

    Time frame: 8 years

  25. AUC 0 - 29d; cellular kinetic parameter of tisagenlecleucel

    Impact of tisagenlecleucel exposure on day 29 response; The AUC from time zero to day 29 in peripheral blood (% or copies/μg x days )

    Time frame: Day 29

  26. Cmax: cellular kinetic parameter of tisagenlecleucel

    Impact of tisagenlecleucel exposure on day 29 response; The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (% or copies/μg)

    Time frame: Day 29

  27. Tmax: cellular kinetic parameter of tisagenlecleucel

    Impact of tisagenlecleucel exposure on day 29 response; The time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days)

    Time frame: Day 29

  28. T1/2: cellular kinetic parameter of tisagenlecleucel

    Impact of tisagenlecleucel exposure on day 29 response; The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood

    Time frame: Day 29

07

Study locations

43 sites
08

References and documents

Publications

  • Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463 ↗
  • Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available. PubMed 32589970 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Oct 2027, 99 months after the start.

Of 92 phase 2 interventional studies under Burkitt Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 119. This study's planned 99 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2018
First posted
Mar 15, 2019
StartActual
Jun 24, 2019
Primary completionEst.
Oct 19, 2027
CompletionEst.
Oct 19, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876769
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Jun 24, 2019
Primary completion
Oct 19, 2027 (estimated)
Completion
Oct 19, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisagenlecleucel

Start the discussion